BR112015018923A2 - terapia celular no tratamento de neurodegeneração - Google Patents

terapia celular no tratamento de neurodegeneração

Info

Publication number
BR112015018923A2
BR112015018923A2 BR112015018923A BR112015018923A BR112015018923A2 BR 112015018923 A2 BR112015018923 A2 BR 112015018923A2 BR 112015018923 A BR112015018923 A BR 112015018923A BR 112015018923 A BR112015018923 A BR 112015018923A BR 112015018923 A2 BR112015018923 A2 BR 112015018923A2
Authority
BR
Brazil
Prior art keywords
neurodegeneration
ncs
treatment
caused
cell therapy
Prior art date
Application number
BR112015018923A
Other languages
English (en)
Other versions
BR112015018923B1 (pt
Inventor
Sasaki Keishin
Koga Minako
N Chase Thomas
Original Assignee
Nc Medical Res Inc
N Chase Thomas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nc Medical Res Inc, N Chase Thomas filed Critical Nc Medical Res Inc
Publication of BR112015018923A2 publication Critical patent/BR112015018923A2/pt
Publication of BR112015018923B1 publication Critical patent/BR112015018923B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)

Abstract

resumo “terapia celular no tratamento de neurodegeneração” os métodos são descritos para o isolamento e seleção de uma população celular heterogênea de medula óssea, chamado ncs-01, que é eficaz no tratamento de neurodegeneração. por exemplo, células ncs-01 são mostradas para tratar a neurodegeneração causada por isquemia. estudos in vivo demonstram que as populações ncs-01 de células selecionados tratam a neurodegeneração em um meio modelo animal de ratos padrão de oclusão da artéria cerebral (mcao) em condições de oclusão total arterial transitória ou permanente. estes estudos revelam também que quando a neurodegeneração é causada por acidente vascular cerebral isquêmico, combinando a administração de uma população de células selecionada ncs-01 com agentes trombolíticos e/ou meios mecânicos de remoção do coágulo conduz a uma diminuição no volume de enfarte a neurodegeneração causada por início agudo. a terapia celular divulgada promete ter um impacto clínico significativo na sobrevida dos pacientes após o avc.
BR112015018923-7A 2013-02-06 2013-02-06 Métodos in vitro de produção de subpopulação heterogênea de células de medula óssea e para otimizar protocolo experimental para isolar população de células que trata neurodegeneração causada por acidente vascular cerebral isquêmico BR112015018923B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/024826 WO2014123516A1 (en) 2013-02-06 2013-02-06 Cell therapy for the treatment of neurodegeneration

Publications (2)

Publication Number Publication Date
BR112015018923A2 true BR112015018923A2 (pt) 2017-07-18
BR112015018923B1 BR112015018923B1 (pt) 2022-03-03

Family

ID=51259382

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015018923-7A BR112015018923B1 (pt) 2013-02-06 2013-02-06 Métodos in vitro de produção de subpopulação heterogênea de células de medula óssea e para otimizar protocolo experimental para isolar população de células que trata neurodegeneração causada por acidente vascular cerebral isquêmico

Country Status (8)

Country Link
US (3) US10071144B2 (pt)
EP (2) EP2953473B1 (pt)
JP (1) JP6156889B2 (pt)
CN (4) CN107362357B (pt)
BR (1) BR112015018923B1 (pt)
ES (1) ES2712719T3 (pt)
TW (2) TWI614341B (pt)
WO (1) WO2014123516A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9733236B2 (en) 2014-04-10 2017-08-15 James L. Sherley Methods for determining the effect of an agent on tissue stem cells
US20230190816A1 (en) * 2020-01-08 2023-06-22 Foundation For Biomedical Research And Innovation At Kobe Physical function recovery promoter

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108759A (en) 1987-04-01 1992-04-28 Ranney David F Endothelial envelopment drug carriers
US5733542A (en) 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5811094A (en) 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5633283A (en) 1995-01-23 1997-05-27 Eli Lilly And Company Method for treating multiple sclerosis
US6653134B2 (en) 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US5945432A (en) 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
JP2002523085A (ja) 1998-08-31 2002-07-30 ニューヨーク・ユニバーシティ 細胞表面にｆｇｆレセプターを坦持する幹細胞
GB9825948D0 (en) 1998-11-26 1999-01-20 Kings College University Of Lo Diagnosis of spongiform disease
US8017112B2 (en) 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
JP2002544234A (ja) * 1999-05-14 2002-12-24 ヘンリー フォード ヘルス システム 発作の処置のための骨髄移植
US20050169896A1 (en) 1999-05-14 2005-08-04 Henry Ford Health System Bone marrow transplantation for treatment of stroke
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
JP5102931B2 (ja) * 2001-01-09 2012-12-19 マイクロベンション インコーポレイテッド 塞栓摘出用カテーテルおよび該カテーテルを有するシステム
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US20040259254A1 (en) 2001-10-30 2004-12-23 Osamu Honmou Method for inducing differentiation mesodermal stem cells, es cells or immortalized cells into nervous system cells
WO2003038074A1 (fr) 2001-10-30 2003-05-08 Renomedix Institute Inc. Procede d'induction de differenciation de cellules souches de mesoblastes ou de cellules es dans des cellules du systeme nerveux
US20060113731A1 (en) * 2004-11-17 2006-06-01 Franco Stocchiero Sealing ring to be applied to connection holes of cells of an accumulator
DE10259703A1 (de) * 2002-12-19 2004-07-08 Ivonex Gmbh Trennungsverfahren
US7807458B2 (en) * 2003-01-30 2010-10-05 The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs Multilineage-inducible cells and uses thereof
US20070178591A1 (en) 2004-06-25 2007-08-02 Renomedix Institute, Inc Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient
EP1658853A4 (en) 2003-06-27 2009-07-08 Renomedix Inst Inc MEDIUM FOR INTERNAL ADMINISTRATION FOR DISEASES OF NERVES IN THE HEAD WITH MESENCYCLES AS AN ACTIVE SUBSTANCE
EP1640898A4 (en) 2003-06-27 2011-01-12 Nc Medical Res Inc INTRINSIC CELL DELIVERY SYSTEM FOR MEDICAL CARE, FINANCIAL SYSTEM FOR ASSISTANCE IN DELIVERY OF INTRINSIC CELLS FOR MEDICAL CARE, AND CORRESPONDING METHODS
CN100424171C (zh) * 2004-08-16 2008-10-08 北京赛生药业有限公司 高纯度蛇毒纤溶酶的制备方法及其药物制剂
US7712027B2 (en) 2004-08-31 2010-05-04 Research In Motion Limited Method for document page delivery to a mobile communication device
EP1817047B1 (en) * 2004-11-05 2012-02-08 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
WO2006113731A2 (en) * 2005-04-20 2006-10-26 University Of Florida Research Foundation, Inc. Bone marrow-derived neurogenic cells and uses thereof
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
US20070128174A1 (en) * 2005-09-21 2007-06-07 Kleinsek Donald A Methods and compositions for organ and tissue functionality
US9770485B2 (en) * 2006-02-21 2017-09-26 Academia Sinica Methods for rescuing learning and/or memory deficits caused by alzheimer's disease by G-CSF
BRPI0706070A2 (pt) 2006-06-26 2011-03-22 Gambro Bct Inc método de cultivo de células-tronco mesenquimais
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
ES2611021T3 (es) * 2007-09-11 2017-05-04 Sapporo Medical University Método de crecimiento celular y preparación farmacéutica para reparación y regeneración de tejido
EP2168666A1 (en) * 2008-09-25 2010-03-31 Gambro Lundia AB Irradiated membrane for cell expansion
HUE046494T2 (hu) 2008-11-10 2020-03-30 Moleac Pte Ltd Kombinációs kezelés neurológiai rendellenességekben és agyi infarktusban szenvedõ pácienseknek
WO2010056988A2 (en) * 2008-11-13 2010-05-20 University Of South Florida Methods of treating stroke using stem cell-like menstrual blood cells
WO2011130256A2 (en) * 2010-04-13 2011-10-20 Lumen Biomedical, Inc. Embolectomy devices and methods for treatment of acute ischemic stroke condition

Also Published As

Publication number Publication date
EP2953473A1 (en) 2015-12-16
US20180353577A1 (en) 2018-12-13
ES2712719T3 (es) 2019-05-14
WO2014123516A1 (en) 2014-08-14
US20140219969A1 (en) 2014-08-07
CN107362357B (zh) 2021-04-27
TW201444973A (zh) 2014-12-01
US10874723B2 (en) 2020-12-29
CN107362357A (zh) 2017-11-21
CN107260760B (zh) 2021-08-31
TW201819624A (zh) 2018-06-01
JP2016506954A (ja) 2016-03-07
TWI669398B (zh) 2019-08-21
EP2953473B1 (en) 2018-11-28
CN105072914B (zh) 2018-09-21
CN107260760A (zh) 2017-10-20
JP6156889B2 (ja) 2017-07-05
EP2953473A4 (en) 2016-10-12
BR112015018923B1 (pt) 2022-03-03
CN105072914A (zh) 2015-11-18
US10149894B2 (en) 2018-12-11
CN107267449A (zh) 2017-10-20
US20170326211A1 (en) 2017-11-16
US10071144B2 (en) 2018-09-11
CN107267449B (zh) 2021-03-19
EP3456817A1 (en) 2019-03-20
TWI614341B (zh) 2018-02-11

Similar Documents

Publication Publication Date Title
DOP2016000102A (es) (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso
RU2009118942A (ru) Способ стимуляции регенерации тканей
WO2013126590A8 (en) Pharmaceutical composition comprising cd34+ cells
CR20150310A (es) Solución para preservar conductos vasculares
BR112017019189A2 (pt) agente terapêutico celular para tratamento de câncer e terapia de combinação com o mesmo
Mazumdar et al. Treatment of Periapical Lesion with Platelet Rich Fibrin.
BR112015018923A2 (pt) terapia celular no tratamento de neurodegeneração
BR112019018861A2 (pt) Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa
BR112015024897A2 (pt) derivado de fenila
WO2014005153A3 (en) Methods for treating mds1-evi1 mediated cancer
SG11201805358TA (en) Medicament for treating cerebral infarction
CL2015002971A1 (es) Composición biofarmacológica que comprende componentes producidos y/o secretados por células troncales mesenquimales (msc), que permite recuperar la capacidad regenerativa tisular, en una situación de esteatosis hepática, o donde la capacidad de regeneración endógena del tejido hepático se encuentra inhibida
Chen et al. Response to Letter Regarding Article,“Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Study”
BR112018000525A2 (pt) concentrado contendo alprostadil
Chao et al. GW24-e2217 AKAP150 anchored PKC to enhance cardiomyocyte damage in diabetes
Zhang et al. Effect of stress hyperglycemia on prognosis of nondiabetic patients with acute myocardial infarction
Zhu et al. Precise hepatic pedicle dissection in anatomical hepatic segmentectomy
Liu et al. Clinical application of the preemptive analgesia of Dezocine on patients with renal transplantation anesthesia
Liu et al. To assess the prognosis of patients with return of spontaneous circulation after cardiac arrest by shock index and adjusted shock index
Lowry Bleeding complications in paediatric patients: 3 case reports
Liu et al. The emergency treatment and prevention of complications for 87 patients with severe traumatic shock
Han A Case of Cerebral Infarction in Atrial Fibrillation Caused by Interruption of Warfarin Therapy for Colonoscopy
Mahasen et al. Sporadic lateral ventricular hemangioblastoma presenting with Intraventricular and Subarachnoid Haemorrhage
Zhu et al. Renin-angiotensin-aldosterone system changes in pediatric severe sepsis treated with continuous blood purification
Yukai et al. GW24-e2211 Protective effects of aliskiren on ischaemia-reperfusion-induced renal injury in rats

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NC MEDICAL RESEARCH INC (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/02/2013, OBSERVADAS AS CONDICOES LEGAIS.